AI-1008

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameAI-1008
Drug Alias NameAbl-kinase inhibitor (Incozen)AI-1008
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBcr-Abl tyrosine kinase inhibitors
TargetsBcr-Abl tyrosine kinase
Therapy Area/IndicationsGastrointestinal Stromal TumorsLeukemia, Myelogenous, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndia
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesIncozen Therapeutics Pvt Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIncozen Therapeutics Pvt Ltd
Active IndicationsN/A
Inactive IndicationsGastrointestinal Stromal TumorsLeukemia, Myelogenous, Chronic

Other Information

ATC CodeN/A
Related LinksN/A